Literature DB >> 3977595

Tissue specific, acute toxic effects of the carcinogen trans-4-dimethylaminostilbene.

P Marquardt, W Romen, H G Neumann.   

Abstract

The acute toxicity of the carcinogen trans-4-dimethylaminostilbene was studied in Wistar rats. The animals die after oral administration of 50 mg/kg (LD50) with a latency period of 11 days. Specific lesions of the stomach epithelium together with acute bone marrow incapacity and toxic effects on peripheral blood cells lead to acute anemia, which is considered to be the cause of death. Histological observations indicate that the stomach lesions develop in three phases. Firstly, necroses appear in the proliferative area predominantly in the antrum. This leads, secondly, to cystic transformation of the antrum, cardia, and Brunner's glands and further to peptic erosions and ulcerations. Thirdly, mitotic activity increases. With lethal doses, cell replacement remains incomplete. There ist a correlation between the proliferation rate of different cell types and their susceptibility; but this cannot entirely account for the tissue-specific, systemic effects of trans-4-dimethylaminostilbene. Metabolic activation is also involved, since enzyme induction with methylcholanthrene inhibits toxicity. The study disclosed a new target tissue which may now be used to investigate the mechanism of action of reactive metabolites of an aromatic amine in acute experiments. The same stomach lesions were also observed with adriamycin. With this compound, however, the intestine is also involved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3977595     DOI: 10.1007/bf00333419

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  14 in total

1.  [Quantitative study of the carcinogenic effect of 4-amino-stilbenes].

Authors:  R MECKE; D SCHMAHL
Journal:  Z Krebsforsch       Date:  1956

2.  The effect of 1:2:5:6-dibenzanthracene on the lymph-nodes of the rat.

Authors:  A Lasnitzki; D L Woodhouse
Journal:  J Anat       Date:  1944-07       Impact factor: 2.610

Review 3.  Phenacetin abuse: a review.

Authors:  G Carro-Ciampi
Journal:  Toxicology       Date:  1978-08       Impact factor: 4.221

Review 4.  Carcinogenesis by aromatic amines.

Authors:  E Kriek
Journal:  Biochim Biophys Acta       Date:  1974-09-09

5.  Effects of isomers of acetotoluidide and aminobenzoic acid on the toxicity and carcinogenicity of N-2-fluorenylacetamide.

Authors:  R S Yamamoto; H H Frankel; J H Weisburger
Journal:  Toxicol Appl Pharmacol       Date:  1970-07       Impact factor: 4.219

6.  Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.

Authors:  J R Mitchell; D J Jollow; W Z Potter; D C Davis; J R Gillette; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

Review 7.  The metabolic activation of carcinogenic aromatic amines and amides.

Authors:  J A Miller; E C Miller
Journal:  Prog Exp Tumor Res       Date:  1969

8.  Pharmacokinetic parameters influencing tissue specificity in chemical carcinogenesis.

Authors:  H G Neumann
Journal:  Arch Toxicol Suppl       Date:  1979

9.  [The relevance of chemico-biological interactions for the toxic and carcinogenic effects of aromatic amines. I. Carcinogenic activity of some 4-aminostilbene and 4-aminobibenzyl-derivatives].

Authors:  H G Neumann; M Metzler; I Brachmann; C Thomas
Journal:  Z Krebsforsch       Date:  1970

10.  [Importance of chemico-biological interactions for the toxic and carcinogenic effects of aromatic amines. II. Distribution of radioactivity after administration of tritium labelled carcinogen trans-4-dimethylaminostilbene and the noncarcinogenic cis-4-dimethylaminostilbene and dimethyl aminobibenzyl in the rat].

Authors:  H K Rjosk; H G Neumann
Journal:  Z Krebsforsch       Date:  1971-02-26
View more
  1 in total

Review 1.  The role of DNA damage in chemical carcinogenesis of aromatic amines.

Authors:  H G Neumann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.